Since glucosylceramide synthase inhibitors were reported to sensitize CLL cells to chlorambucil and fludarabine induced cell death (43), further experiments are needed to confirm whether SKI-II and opaganib effects on CLL cells are meditated by the inhibition of SHPK2 and/or other molecule(s). The gene discussed is UGCG; the disease is B-cell chronic lymphocytic leukemia.